Transgene Biotek Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 0.45 million. Revenue was INR 0.888 million compared to INR 0.438 million a year ago. Net loss was INR 1.19 million compared to INR 13.79 million a year ago. Basic loss per share from continuing operations was INR 0.02 compared to INR 0.18 a year ago. Diluted loss per share from continuing operations was INR 0.02 compared to INR 0.18 a year ago.
For the nine months, sales was INR 1.9 million compared to INR 0.551 million a year ago. Revenue was INR 3.21 million compared to INR 1.87 million a year ago. Net loss was INR 3.91 million compared to INR 45.37 million a year ago. Basic loss per share from continuing operations was INR 0.05 compared to INR 0.6 a year ago. Diluted loss per share from continuing operations was INR 0.05 compared to INR 0.6 a year ago.